Keyphrases
Glucose-dependent Insulinotropic Polypeptide
100%
Physiological Role
100%
Receptor mutations
28%
Fracture Risk
14%
Bone Cells
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Rodents
14%
Glucagon
14%
Glucose Level
14%
Bone Turnover
14%
Minor Effect
14%
Experimental Support
14%
Diet-induced Obesity
14%
Glucose Intolerance
14%
Bone Metabolism
14%
Glucose Effect
14%
Indirect Observation
14%
Bone Turnover Markers
14%
Receptor Antagonist
14%
Incretin Hormones
14%
Clear Effect
14%
Gastrointestinal
14%
Gut Hormones
14%
Glucose Metabolism
14%
Lipid Metabolism
14%
Healthy Individuals
14%
Inhibitory Effect
14%
Glucagon-like peptide-1 (GLP-1)
14%
Loss Function
14%
Pharmacology, Toxicology and Pharmaceutical Science
Gastric Inhibitory Polypeptide
100%
Gastric Inhibitory Polypeptide Receptor
85%
Receptor Antagonist
14%
Diet Induced Obesity
14%
Glucose Intolerance
14%
Glucagon
14%
Incretin
14%
Non Insulin Dependent Diabetes Mellitus
14%
Glucagon-Like Peptide-1
14%
Gastrointestinal Hormone
14%
Medicine and Dentistry
Gastric Inhibitory Polypeptide
100%
Receptor
38%
Osteolysis
7%
Maturity Onset Diabetes of the Young
7%
Glucagon
7%
Glucose Intolerance
7%
Bone Turnover
7%
Diet Induced Obesity
7%
Gastrointestinal Hormone
7%
Glucagon Like Peptide 1
7%
Bone Remodeling
7%
Incretin
7%
Lipid Metabolism
7%
Glucose Metabolism
7%
Secretion (Process)
7%
Receptor Antagonist
7%